Cardiac Expression of Placental Growth Factor Predicts the Improvement of Chronic Phase Left Ventricular Function in Patients With Acute Myocardial Infarction

Iwama, Hajime; Uemura, Shiro; Naya, Noriyuki; Imagawa, Keiichi; Takemoto, Y.; Asai, Osamu; Onoue, Kenji; Okayama, Satoshi; Somekawa, Satoshi; Kida, Yoshitomi; Takeda, Yukiji; Nakatani, Katsunori; Takaoka, Minoru; Kawata, Hiroyuki; Horii, Manabu; Nakajima, Takahito; Doi, Nobuhide; Saito, Yoshihiko

doi:10.1016/j.jacc.2005.11.064

Cited by 76 publications

(68 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Correlation studies in patients and mouse models indicate that cardiac expression of PlGF promotes wound healing after AMI, possibly by inducing mobilization of mononuclear cells and enhancing angiogenesis (Iwama et al 2006). These data warrant further investigation of whether PlGF therapy may represent a valuable adjunct or alternative to current revascularization strategies for patients with ischemic heart disease.…”

Section: Plgf a Disease-modifying Candidatementioning

confidence: 88%

PlGF: A Multitasking Cytokine with Disease-Restricted Activity

Dewerchin¹,

Carmeliet²

2012

Cold Spring Harbor Perspectives in Medicine

193

176

View full text Add to dashboard Cite

Section: Plgf a Disease-modifying Candidatementioning

confidence: 88%

PlGF: A Multitasking Cytokine with Disease-Restricted Activity

Dewerchin¹,

Carmeliet²

2012

Cold Spring Harbor Perspectives in Medicine

193

176

View full text Add to dashboard Cite

“…11) In patients with chest pain and acute coronary syndrome, higher PlGF levels have been observed in those with MI and are associated with an increased risk of short-and long-term adverse outcomes. [12][13][14] There are conflicting results regarding circulating sFlt-1 levels in patients with CAD, with some studies noting higher levels during acute MI compared with control pa-tients, 15) and others showing lower plasma sFlt-1 levels in patients during the acute phase of MI compared with control subjects. 16,17) Although PlGF and sFlt-1 might be important biomarkers of chronic heart failure, neither factor has been fully studied in patients with heart failure.…”

mentioning

confidence: 99%

Soluble Fms-like Tyrosine Kinase 1 Is a Novel Predictor of Brain Natriuretic Peptide Elevation

et al. 2013

View full text Add to dashboard Cite

SummarySoluble fms-like tyrosine kinase 1 (sFlt-1) is an endogenous inhibitor of vascular endothelial growth factor, which is involved in cardiovascular remodeling and atherosclerosis development. To examine the predictive role of sFlt-1 levels in patients with asymptomatic heart failure, we measured circulating sFlt-1 in patients with or without coronary artery disease (CAD). We analyzed 88 Japanese patients with CAD or patients at high risk for atherosclerosis and who were undergoing total risk management for cardiovascular disease prevention. Circulating sFlt-1 levels correlated with the increase in plasma brain natriuretic peptide levels (ΔBNP) from baseline to the observed levels 5 years later in CAD patients, patients with previous myocardial infarction, and men. ΔBNP levels correlated with sFlt-1 levels in the high-sFlt-1 patients with CAD (r = 0.511, P < 0.01). In all patients, end-systolic volume index (ΔESVI) increased in correlation with a decrease in left ventricular ejection fraction (ΔEF) in the long-term observation, independent of their history of myocardial infarction (ΔESVI = 2.5 mL/m 2 increase/year). Baseline level of sFlt-1 was independent of ΔESVI or ΔEF. The present 5-year observational study demonstrated that high sFlt-1 levels predicted moderate increases in BNP levels in CAD patients. Moreover, ΔBNP was correlated with ΔESVI/year in CAD patients with high-sFlt-1 levels. These data suggest that high sFlt-1 levels may be an effective biomarker to predict the progression of heart failure in patients with CAD. (Int Heart J 2013; 54: 133-139)

show abstract

“…We have recently demonstrated that PlGF is produced rapidly in infarcted myocardial tissue, and that the plasma level of PlGF after MI is positively correlated with the improvement in left ventricular function in patients with AMI. 13 These findings suggest that PlGF is involved in post-AMI pathology, infiltration of inflammatory cells, neoangiogenesis, and the development of fibrosis and thus the healing process after AMI. However, therapeutic effects of PlGF administration have not been studied, so in the present study we investigated the result of exogenous administration of PLGF protein in regard to cardiac function and prognosis after MI.…”

mentioning

confidence: 89%

“…The next day, coronary ligation was performed in the same mouse, as previously reported. 13,16 rhPlGF was infused for 3 days and rhsFlt-1 was infused for 7 days. In total, 95 mice were used for assessing survival rate and 74 mice for histological, physiological and biochemical analyses.…”

Section: Preparation Of Mouse Model Of MImentioning

confidence: 99%

“…10 Secondly, PlGF is able to mobilize EPCs from bone marrow to the peripheral circulation, 17 and finally, we recently observed that PlGF mRNA expression is substantially upregulated in the endothelium of the coronary arteries and interstitial cells in the infarct regions, suggesting participation of PlGF in the pathology of AMI. 13 Some previous investigations revealed that transfer of the PlGF gene or direct injection of PlGF protein induced angiogenesis in ischemic hindlimb and myocardium. 9,10 Moreover, Autiero et al reported that intraperitoneal injection of a VEGF/PlGF heterodimer enhanced angiogenesis 2 weeks after AMI.…”

Section: Exogenous Plgf Improves the Prognosis Of MI Via Angiogenesismentioning

confidence: 99%

See 1 more Smart Citation

Treatment With Recombinant Placental Growth Factor (PlGF) Enhances Both Angiogenesis and Arteriogenesis and Improves Survival After Myocardial Infarction

Takeda

Uemura

Iwama

et al. 2009

Circ J

Self Cite

View full text Add to dashboard Cite

Background: Placental growth factor (PlGF), a homolog of vascular endothelial growth factor, is reported to stimulate angiogenesis and arteriogenesis in pathological conditions. It was recently demonstrated that PlGF is rapidly produced in myocardial tissue during acute myocardial infarction (MI). However, the effects of exogenous PlGF administration on the healing process after MI are not fully understood. The purpose of the present study was to examine whether PlGF treatment has therapeutic potential in MI. Methods and Results: Recombinant human PlGF (rhPlGF: 10 μg) was administered continuously for 3 days in a mouse model of acute MI. rhPlGF treatment significantly improved survival rate after MI and preserved cardiac function relative to control mice. The numbers of CD31-positive cells and α-smooth muscle actin-positive vessels in the infarct area were significantly increased in the rhPlGF group. Endothelial progenitor cells (Flk-1 + Sca-1 + cells) were mobilized by rhPlGF into the peripheral circulation. Furthermore, rhPlGF promoted the recruitment of GFP-labeled bone marrow cells to the infarct area, but only a few of those migrating cells differentiated into endothelial cells. Conclusions: Exogenous PlGF plays an important role in healing processes by improving cardiac function and stimulating angiogenesis following MI. It can be considered as a new therapeutic molecule. (Circ J 2009; 73: 1674 -1682

show abstract

Cardiac Expression of Placental Growth Factor Predicts the Improvement of Chronic Phase Left Ventricular Function in Patients With Acute Myocardial Infarction

Cited by 76 publications

References 41 publications

PlGF: A Multitasking Cytokine with Disease-Restricted Activity

PlGF: A Multitasking Cytokine with Disease-Restricted Activity

Soluble Fms-like Tyrosine Kinase 1 Is a Novel Predictor of Brain Natriuretic Peptide Elevation

Treatment With Recombinant Placental Growth Factor (PlGF) Enhances Both Angiogenesis and Arteriogenesis and Improves Survival After Myocardial Infarction

Contact Info

Product

Resources

About